The world is currently experiencing a huge challenge which has affected all the industries and markets. Few markets have experienced a high growth in their demand while others have faced a downfall. The extent of growth or drop in the market statistics of different industries by COVID 19 plays an important role in how the future of businesses will shape up in the near future. We at Value Market Research provide you with an impact analysis of COVID 19 on this market with its latest update in the purchased version of the report.
Global Intravenous Pegloticase Market Report By Age Group (Pediatric,Adult,Geriatric), By indication,Chronic,Refractory,,By distribution channnel,Hospital pharmacies,Retail Pharmacies,Others ) And By Regions - Industry Trends, Size, Share, Growth, Estimation and Forecast, 2021-2028
ID:VMR11213865
April 2021
Report Formats: Electronic (PDF), MS EXCEL
The global demand for Intravenous Pegloticase Market is presumed to reach the valuation of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period of 2022-2028.
Intravenous pegloticase is an infusion used to treat chronic refractory gout in adults by reducing the uric acid levels. This biologic therapy is generally used in patients who have not responded to the usual treatments. The medication is given regularly every two weeks to get the most benefit from it. More gout attacks for many months after starting this medicine are expected. Pegloticase is to be given only by a healthcare professional. It is not recommended for treating asymptomatic hyperuricemia. This treatment has a potent and long-lasting urate-lowering capacity with rapid efficacy.
Market Dynamics
Intravenous pegloticase, the only available, FDA-approved treatment for adult patients with chronic gout refractory for whom conventional oral urate-lowering medications have contraindicated, is the primary impetus for the growth of this market. The increased prevalence of chronic and refractory gout diseases among the global population will favor market growth. The growing mergers and collaborations between healthcare facilities, pharmaceutical manufacturers, and research communities in developing an efficient treatment for chronic and refractory gout will boost the market growth. This treatment’s rising awareness and adoption to manage chronic and refractory gout disease effectively will be a market booster. The various allergic reactions like anaphylaxis caused by this treatment will be the main restraining factor for the market growth.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each segment in the global market of intravenous pegloticase.
Market Segmentation
This section of the intravenous pegloticase market report provides detailed data on the segments by analyzing them geographically, thereby assisting the strategist in identifying the target demographics for the respective product or service.
By Age Group
By Indication
By Distribution Channnel
Regional Analysis
This section covers regional segmentation which accentuates on current and future demand for Intravenous Pegloticase market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Intravenous Pegloticase Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the intravenous pegloticase market include Horizon Therapeutics,BTG plc,Savient Pharmaceuticals Inc,OthersS. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
Intravenous pegloticase is an infusion used to treat chronic refractory gout in adults by reducing the uric acid levels. This biologic therapy is generally used in patients who have not responded to the usual treatments. The medication is given regularly every two weeks to get the most benefit from it. More gout attacks for many months after starting this medicine are expected. Pegloticase is to be given only by a healthcare professional. It is not recommended for treating asymptomatic hyperuricemia. This treatment has a potent and long-lasting urate-lowering capacity with rapid efficacy.
Market Dynamics
Intravenous pegloticase, the only available, FDA-approved treatment for adult patients with chronic gout refractory for whom conventional oral urate-lowering medications have contraindicated, is the primary impetus for the growth of this market. The increased prevalence of chronic and refractory gout diseases among the global population will favor market growth. The growing mergers and collaborations between healthcare facilities, pharmaceutical manufacturers, and research communities in developing an efficient treatment for chronic and refractory gout will boost the market growth. This treatment’s rising awareness and adoption to manage chronic and refractory gout disease effectively will be a market booster. The various allergic reactions like anaphylaxis caused by this treatment will be the main restraining factor for the market growth.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each segment in the global market of intravenous pegloticase.
Market Segmentation
This section of the intravenous pegloticase market report provides detailed data on the segments by analyzing them geographically, thereby assisting the strategist in identifying the target demographics for the respective product or service.
By Age Group
- Pediatric
- Adult
- Geriatric
By Indication
- Chronic
- Refractory
By Distribution Channnel
- Hospital pharmacies
- Retail Pharmacies
- Others
Regional Analysis
This section covers regional segmentation which accentuates on current and future demand for Intravenous Pegloticase market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Intravenous Pegloticase Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the intravenous pegloticase market include Horizon Therapeutics,BTG plc,Savient Pharmaceuticals Inc,OthersS. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
1 . PREFACE
1.1. Report Description
1.1.1. Objective
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . INTRAVENOUS PEGLOTICASE – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 By Age Group
3.7.2 By Indication
3.7.3 By Distribution Channnel
3.7.4 By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5. IMPACT ANALYSIS OF COVID-19 OUTBREAK
5.1. Impact Analysis of Covid-19 Outbreak
5.1.1. Direct Impact on Production
5.1.2. Supply Chain and Market Disruption
5.1.3. Financial Impact on Firms and Financial Markets
5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
5.3. Market: Pre V/S Post COVID-19
5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
5.5. COVID-19: Micro and Macro Factor Analysis
6 . GLOBAL INTRAVENOUS PEGLOTICASE MARKET ANALYSIS BY AGE GROUP
6.1 Overview by Age Group
6.2 Historical and Forecast Data
6.3 Analysis by Age Group
6.4 Pediatric Market by Regions
6.6 Adult Market by Regions
6.5 Geriatric Market by Regions
7 . GLOBAL INTRAVENOUS PEGLOTICASE MARKET ANALYSIS BY INDICATION
7.1 Overview by Indication
7.2 Historical and Forecast Data
7.3 Analysis by Indication
7.4 Chronic Market by Regions
7.5 Refractory Market by Regions
8 . GLOBAL INTRAVENOUS PEGLOTICASE MARKET ANALYSIS BY DISTRIBUTION CHANNNEL
8.1 Overview by Distribution Channnel
8.2 Historical and Forecast Data
8.3 Analysis by Distribution Channnel
8.4 Hospital pharmacies Market by Regions
8.5 Retail Pharmacies Market by Regions
8.6 Others Market by Regions
9 . GLOBAL INTRAVENOUS PEGLOTICASE MARKET ANALYSIS BY GEOGRAPHY
9.1. Regional Outlook
9.2. Introduction
9.3. North America
9.3.1. Overview, Historic and Forecast Data
9.3.2. North America By Segment
9.3.3. North America By Country
9.3.4. United State
9.3.5. Canada
9.3.6. Mexico
9.4. Europe
9.4.1. Overview, Historic and Forecast Data
9.4.2. Europe by Segment
9.4.3. Europe by Country
9.4.4. United Kingdom
9.4.5. France
9.4.6. Germany
9.4.7. Italy
9.4.8. Russia
9.4.9. Rest Of Europe
9.5. Asia Pacific
9.5.1. Overview, Historic and Forecast Data
9.5.2. Asia Pacific by Segment
9.5.3. Asia Pacific by Country
9.5.4. China
9.5.5. India
9.5.6. Japan
9.5.7. South Korea
9.5.8. Australia
9.5.9. Rest Of Asia Pacific
9.6. Latin America
9.6.1. Overview, Historic and Forecast Data
9.6.2. Latin America by Segment
9.6.3. Latin America by Country
9.6.4. Brazil
9.6.5. Argentina
9.6.6. Peru
9.6.7. Chile
9.6.8. Rest of Latin America
9.7. Middle East & Africa
9.7.1. Overview, Historic and Forecast Data
9.7.2. Middle East & Africa by Segment
9.7.3. Middle East & Africa by Country
9.7.4. Saudi Arabia
9.7.5. UAE
9.7.6. Israel
9.7.7. South Africa
9.7.8. Rest Of Middle East And Africa
10 . COMPETITIVE LANDSCAPE OF THE INTRAVENOUS PEGLOTICASE COMPANIES
10.1. Intravenous Pegloticase Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments
11 . COMPANY PROFILES OF INTRAVENOUS PEGLOTICASE INDUSTRY
11.1. Company Share Analysis
11.2. Market Concentration Rate
11.3. Horizon Therapeutics
11.3.1. Company Overview
11.3.2. Financials
11.3.3. Products
11.3.4. Recent Developments
11.4. BTG plc
11.4.1. Company Overview
11.4.2. Financials
11.4.3. Products
11.4.4. Recent Developments
11.5. Savient Pharmaceuticals Inc.
11.5.1. Company Overview
11.5.2. Financials
11.5.3. Products
11.5.4. Recent Developments
11.6. Others
11.6.1. Company Overview
11.6.2. Financials
11.6.3. Products
11.6.4. Recent Developments
*Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
LIST OF TABLES
- Market Snapshot
- Drivers : Impact Analysis
- Restraints : Impact Analysis
- List of Raw Material
- List of Raw Material Manufactures
- List of Potential Buyers
- COVID-19 Impact Analysis by Production, Import, Export and Demand
- Pre V/S Post COVID-19
- Estimated Impact Of The Coronavirus (Covid-19) Epidemic
- COVID-19: Micro and Macro Factor Analysis
- Analysis by Age Group (USD MN)
- Pediatric Market by Geography (USD MN)
- Adult Market by Geography (USD MN)
- Geriatric Market by Geography (USD MN)
- Analysis Market by Indication (USD MN)
- Chronic Market by Geography (USD MN)
- Refractory Market by Geography (USD MN)
- Analysis by Distribution Channnel (USD MN)
- Hospital pharmacies Market by Geography (USD MN)
- Retail Pharmacies Market by Geography (USD MN)
- Others Market by Geography (USD MN)
- Global Intravenous Pegloticase Market by Geography (USD MN)
- North America Market Analysis (USD MN)
- United State Market Analysis (USD MN)
- Canada Market Analysis (USD MN)
- Mexico Market Analysis (USD MN)
- Europe Market Analysis (USD MN)
- Europe Market Estimate by Country (USD MN)
- United Kingdom Market Analysis (USD MN)
- France Market Analysis (USD MN)
- Germany Market Analysis (USD MN)
- Italy Market Analysis (USD MN)
- Russia Market Analysis (USD MN)
- Spain Market Analysis (USD MN)
- Rest of Europe Market Analysis (USD MN)
- Asia Pacific Market Analysis (USD MN)
- China Market Analysis (USD MN)
- Japan Market Analysis (USD MN)
- India Market Analysis (USD MN)
- South Korea Market Analysis (USD MN)
- Australia Market Analysis (USD MN)
- Rest of Asia Pacific Market Analysis (USD MN)
- Latin America Market Analysis (USD MN)
- Brazil Market Analysis (USD MN)
- Argentina Market Analysis (USD MN)
- Peru Market Analysis (USD MN)
- Chile Market Analysis (USD MN)
- Rest of Latin America Market Analysis (USD MN)
- Middle East & Africa Market Analysis (USD MN)
- Saudi Arabia Market Analysis (USD MN)
- UAE Market Analysis (USD MN)
- Israel Market Analysis (USD MN)
- South Africa Market Analysis (USD MN)
- Rest of Middle East and Africa Market Analysis (USD MN)
- Partnership/Collaboration/Agreement
- Mergers And Acquisiton
LIST OF FIGURES
- Research Scope of Intravenous Pegloticase Report
- Market Research Process
- Market Research Methodology
- Global Intravenous Pegloticase Market Size, by Region (USD MN)
- Porters Five Forces Analysis
- Market Attractiveness Analysis by Age Group
- Market Attractiveness Analysis by Indication
- Market Attractiveness Analysis by Distribution Channnel
- Market Attractiveness Analysis by Region
- Value Chain Analysis
- Global Market Analysis by Age Group (USD MN)
- Pediatric Market by Geography (USD MN)
- Adult Market by Geography (USD MN)
- Geriatric Market by Geography (USD MN)
- Global Market Analysis by Indication (USD MN)
- Chronic Market by Geography (USD MN)
- Refractory Market by Geography (USD MN)
- Global Market Analysis by Distribution Channnel (USD MN)
- Hospital pharmacies Market by Geography (USD MN)
- Retail Pharmacies Market by Geography (USD MN)
- Others Market by Geography (USD MN)
- Global Market by Revenue
- North America Market by Revenue
- Europe Market by Revenue
- Asia Pacific Market by Revenue
- Latin America Market by Revenue
- Middle East & Africa Market by Revenue
- Recent Development in Industry
- Company Market Share Analysis
* Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.
Related Categories
Healthcare
Buy Chapters or Sections
Avail customized purchase options to meet your exact research needs:
- Buy sections of this report
- Buy country level reports
- Request for historical data
- Request discounts available for Start-Ups & Universities
Objectives of Study
- Define and measure the global market
- Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
- Analyze and identify major market trends along with the factors driving or inhibiting the market growth
- Study the company profiles of the major market players with their market share
- Analyze competitive developments